Abstracts tagged "alkaline phosphatase"

Abstract Number: 195 • 2019 ACR/ARP Annual Meeting
The Clinical Characteristics of Patients with Inflammatory Arthritis and a Persistently Low Alkaline Phosphatase Level in a Veteran Affairs Rheumatology Clinic
Luke Monteagudo¹, Amy Gravely ², Peter Valen ³ and David Ewart ³, ¹The University of Minnesota, Minneapolis, ²Minneapolis Veteran Affairs Medical Center, Minneapolis, ³University of Minnesota School of Medicine/ Minneapolis Veteran Affairs Medical Center, Minneapolis
Background/Purpose: Background: The biochemical hallmark of hypophosphatasia (HPP) is a low alkaline phosphatase (ALP) level. It is recognized that some forms of HPP present in adulthood…
Abstract Number: 2227 • 2019 ACR/ARP Annual Meeting
Can We Predict Hypophosphatasia-Mutation Result Based on Alkaline Phosphatase Serum Levels?
Carolina Tornero¹, Victoria Navarro-Compán ², Jair Antonio Tenorio ³, Sara García ⁴, Antonio Buño ⁵, Irene Monjo ⁶, Chamaida Plasencia ⁷, Jose María Iturzaeta ⁸, Pablo Lapunzina ³, Karen Heath ³, Alejandro Balsa ⁷ and Pilar Aguado ¹, ¹Rheumatology Department. La Paz University Hospital., Madrid, ²University Hospital La Paz, IdiPaz, Madrid, Spain, ³Genetics Department. La Paz University Hospital. CIBERER, Madrid, ⁴Rheumatology Department. La Paz University Hospital, Madrid, ⁵Clinical Biochemistry, La Paz University Hospital, Madrid, ⁶FIBHULP-IdiPAZ-Hospital La Paz-Rheumatology, Madrid, Spain, ⁷Immuno-Rheumatology Research Group, IdiPaz & Rheumatology Department. La Paz University Hospital, Madrid, Spain, ⁸Clinical Biochemisty. La Paz University Hospital, Madrid
Background/Purpose: Hypophosphatasia (HPP) is caused by mutations in ALPL, resulting in low alkaline phosphatase (ALP) levels. The determination of ALPL mutation may not be accessible…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].